

# Resource Summary Report

Generated by [RRID](#) on Sep 3, 2026

## UOK262

RRID:CVCL\_1D72

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_1D72

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_1D72](https://web.expasy.org/cellosaurus/CVCL_1D72)

**Proper Citation:** RRID:CVCL\_1D72

**Description:** Cell line UOK262 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Hereditary leiomyomatosis and renal cell carcinoma

**Defining Citation:** [PMID:19963135](#), [PMID:21907923](#), [PMID:22867999](#), [PMID:27993170](#), [PMID:33402335](#)

**Comments:** Population: Caucasian.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** UOK262

**Synonyms:** UOK-262, UOK 262

**Cross References:** BTO:BTO\_0005727, Wikidata:Q54991416

**ID:** CVCL\_1D72

**Record Creation Time:** 20220427T221701+0000

**Record Last Update:** 20260830T000237+0000

---

### Ratings and Alerts

No rating or validation information has been found for UOK262.

No alerts have been found for UOK262.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 5 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Najera SS, et al. (2025) Targeting NAD<sup>+</sup> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82. *Molecular cancer therapeutics*, 24(2), 200.

Zacharias NM, et al. (2025) Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma. *Molecular cancer therapeutics*.

Noronha KJ, et al. (2024) NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion. *Molecular cancer research : MCR*, 22(10), 973.

Wilde BR, et al. (2023) FH Variant Pathogenicity Promotes Purine Salvage Pathway Dependence in Kidney Cancer. *Cancer discovery*, 13(9), 2072.

Ge X, et al. (2022) Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma. *Molecular cell*, 82(7), 1249.